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Abstract
Objective
Here, we applied a multi-omics approach (i) to examine molecular pathways related to de-
and remyelination in multiple sclerosis (MS) lesions; and (ii) to translate these findings to the
CSF proteome in order to identify molecules that are differentially expressed among MS
subtypes.
Methods
To relate differentially expressed genes in MS lesions to de- and remyelination, we com-
pared transcriptome of MS lesions to transcriptome of cuprizone (CPZ)-induced de- and
remyelination. Protein products of the overlapping orthologous genes were measured within
the CSF by quantitative proteomics, parallel reaction monitoring (PRM). Differentially regu-
lated proteins were correlated with molecular markers of inflammation by using MesoScale
multiplex immunoassay. Expression kinetics of differentially regulated orthologous genes
and proteins were examined in the CPZ model.
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Results
In the demyelinated and remyelinated corpus callosum, we detected 1239 differentially
expressed genes; 91 orthologues were also differentially expressed in MS lesions. Pathway
analysis of these orthologues suggested that the TYROBP (DAP12)-TREM2 pathway,
TNF-receptor 1, CYBA and the proteasome subunit PSMB9 were related to de- and remyeli-
nation. We designed 129 peptides representing 51 orthologous proteins, measured them by
PRM in 97 individual CSF, and compared their levels between relapsing (n = 40) and pro-
gressive MS (n = 57). Four proteins were differentially regulated among relapsing and pro-
gressive MS: tyrosine protein kinase receptor UFO (UFO), TIMP-1, apolipoprotein C-II
(APOC2), and beta-2-microglobulin (B2M). The orthologous genes/proteins in the mouse
brain peaked during acute remyelination. UFO, TIMP-1 and B2M levels correlated inversely
with inflammation in the CSF (IL-6, MCP-1/CCL2, TARC/CCL17). APOC2 showed positive
correlation with IL-2, IL-16 and eotaxin-3/CCL26.
Conclusions
Pathology-based multi-omics identified four CSF markers that were differentially expressed
in MS subtypes. Upregulated TIMP-1, UFO and B2M orthologues in relapsing MS were
associated with reduced inflammation and reflected reparatory processes, in contrast to the
upregulated orthologue APOC2 in progressive MS that reflected changes in lipid metabo-
lism associated with increased inflammation.
Introduction
Early in the course of multiple sclerosis (MS), disruption of the blood-brain barrier (BBB) and
focal inflammatory demyelination result in acute clinical symptoms followed by recovery
(relapsing-remitting, RRMS) [1]. A cascade of events leads to diffuse axonal and neuronal
degeneration, and if untreated, RRMS converts into a secondary progressive phase (SPMS) in
about 50% of patients; the disease has a progressive course from the onset (primary progres-
sive, PPMS) in about 10–20% of patients [2–4]. A period of diagnostic uncertainty regarding
the transition from RRMS to SPMS lasts for several years, and immunomodulatory treatments
are less efficacious in progressive disease [5,6]. Biomarkers are needed that predict the natural
course and select patients with demand of early highly efficacious treatments.
Cuprizone (CPZ) is a copper chelator, which induces demyelination and oligodendrocyte
loss in the corpus callosum and superior cerebellar peduncles of C57BL/6 mice. Suspension of
CPZ treatment results in rapid remyelination [7–9]. Some of the mechanisms of oligodendro-
cyte death overlap with those observed in dying oligodendrocytes of MS lesions [9,10]. Adap-
tive immune responses are absent or minor in the CPZ model, and the blood-brain barrier
(BBB) remains intact in contrast to the inflammatory model of MS, experimental autoimmune
encephalomyelitis (EAE) [11].
Omics approaches are promising holistic tools for revealing molecular pathways and
quantifying differentially expressed molecules [12]. Focused, hypothesis-driven exploratory
translational omics are promising players in omics-driven precision medicine [13]. The cere-
brospinal fluid (CSF) is the most proximal body fluid to the central nervous system (CNS),
and has been used for biomarker discovery by proteomics in a number of neurological diseases
[14].
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Here, we hypothesized that combination of omics may focus attention on the importance
of certain pathways and molecules in the pathogenesis of multiple sclerosis, and this way we
may also identify molecules that are differentially regulated in the CSF of relapsing versus pro-
gressive MS. First, we established the transcriptome of experimental de- and remyelination in
the CPZ model, and compared the differentially expressed genes to MS lesion transcriptomes
in order to identify cellular pathways associated with de- and remyelination in MS. Protein
products of overlapping orthologous genes were then screened in the CSF proteome of MS
patients, and compared by targeted quantitative proteomics between relapsing and progressive
MS. The differentially regulated proteins were correlated with markers of inflammation in the
CSF of patients with RRMS, and the expression kinetics of orthologous genes and proteins
were examined during demyelination and remyelination in the CPZ model.
Materials and methods
Mice
Wild-type C57BL/6 mice were obtained from Taconic Ltd. (Ry, Denmark). Mice were bred at
the Biomedical Laboratory, SDU according to protocols and guidelines approved by the Dan-
ish Animal Health Care Committee (2014-15-00369). All animal experiments complied with
the EU Directive 2010/63/EU for animal experiments, and the study has received approval by
the Institutional Animal Care and Use Committee of the University of Southern Denmark,
Odense, Denmark. Male mice aged 7–8 weeks were included in the experiments.
Patients
CSF samples were obtained from 30 patients with PPMS (mean age 49±8.6, 17 females), 27
patients with SPMS (45.9±5.8, 14 females), and 40 patients with RRMS (mean age 33.6±10
years, 31 females). Ten subjects of each MS group were used as a discovery cohort for full pro-
teomics of the CSF (cohort 1, altogether 30 MS). In the discovery phase, 10 subjects without
neurological disease with diagnostic CSF examination due to headache were also included
(mean age 37.7±12.8 years, 7 females). All individual samples from the total MS cohort (cohort
1 and 2, altogether 97 MS samples) were used for quantification of selected peptides by tar-
geted proteomics in relapsing and progressive MS subtypes (Fig 1). The CSF was immediately
centrifuged at 400 x g for 10 minutes, supernatant was collected and stored at -80˚C. The study
was conducted in accordance with the approval of the Danish National Ethics Committee (S-
20120066) and informed consent was obtained from each subject.
CPZ-induced demyelination and remyelination
To induce demyelination, powdered standard chow was mixed with 0.2% CPZ (Sigma Aldrich,
MO, USA) and administrated for 2 and 4 weeks. Remyelination was examined after 2 days
(acute remyelination) or 2 weeks (full remyelination) of regular diet following 4-weeks CPZ
feeding. Mice untreated with CPZ were used as controls, and their age and sex were matched
to the 4-week demyelination group. Experiments were terminated by euthanizing mice with
an overdose of pentobarbital (Glostrup Apotek, Glostrup, Denmark) followed by perfusion
with 4% paraformaldehyde (PFA) for staining applications, or phosphate buffered saline for all
other applications.
RNA extraction from the corpus callosum
For the removal of the corpus callosum, the brains were removed from the skull, immediately
frozen and cut into coronal serial sections (section thickness 200 μm). By using a
Multi-omics in multiple sclerosis
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stereomicroscope, the corpus callosum was cut out of the sections with a fine Graefe-knife,
along its rostro-caudal extension, the samples were collected in ice-cold Eppendorf-tubes and
stored frozen until used. RNA was extracted by the miRNeasy micro Kit (Qiagen, Valencia,
CA). The quantity and quality of total RNA was assessed by NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA), respectively. Only those samples that gave>8.0 for RNA integ-
rity number, showed a clear gel image and no DNA contamination was observed on the histo-
gram were used for microarray experiments.
Microarray
For RNA profiling in untreated controls, during demyelination, acute and full remyelination
in the CC, the Agilent Whole Mouse Genom Expression Microarray Kit (G4122F, 4x44K) was
applied according to the manufacturer’s instruction (version 1.0) with 100 ng quality-checked
total RNA: 3–6 mice were used for each condition. The labeled samples were hybridized for 20
hours at 55˚C. The arrays were scanned with an Agilent DNA Microarray Scanner BA, the sig-
nal quantification was carried out by Feature Extraction 10.7 Image Analysis Software and
data were further analyzed by Genespring GX10.0.
The microarray data are deposited in NCBI Gene Expression Omnibus with accession
GSE100663.
Meso scale discovery electrochemiluminescent assay
Biomarker levels in the CSF were measured by the Meso Scale Discovery (MDS) technique
(Mesoscale Discovery, Rockville, USA): Human Proinflammatory Panel 1 V-Plex (IFNγ, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-12p70, TNFα); Human Cytokine Panel 1 V-Plex (GM-CSF, IL-1α,
IL-5, IL-7, IL-23/IL-12p40, IL-15, IL-16, IL-17α, TNFβ, VEGF); Human Angiogenesis Panel 1
V-Plex (VEGF-C, VEGF-D, Flt-1, PIGF, βFGF); Vascular Injury Panel 2 V-Plex (SAA,
VCAM-1, ICAM-1); Human Chemokine Panel 1 (MCP-1, MCP-4, Eotaxin, IP-10, MDC,
Eotaxin-3, TARC, MIP-1α, MIP1β, IL-8). Samples were diluted and loaded into each well
before reading by a SECTOR Imager 6000 Plate Reader (MSD Mesoscale Discovery, USA)
according to the manufacturer’s instructions. Data was analyzed using MSD Discovery Work-
bench software.
Histopathology
Before histological analysis, brains of mice (untreated controls, DEM, aREM, fREM) were
postfixed in 4% PFA overnight and embedded in paraffin. Then, 8 μm coronal sections were
obtained at the levels of 161, 181, 209 and 221. Demyelination was evaluated using Luxol fast
blue staining with cresyl violet, and axonal pathology was examined by Bielschowsky staining.
Immunocytochemistry was performed on paraffin sections as described before [16] without
Fig 1. Outline of the experimental design. The transcriptome of punched out corpus callosum was examined at 4 time points in the cuprizone
(CPZ) model: early and full demyelination (2 and 4 week CPZ, DEM), acute remyelination (aREM, 2 days after suspending CPZ) and full
remyelination (fREM, 14 days after suspending CPZ) by 4x44K Agilent Whole Mouse Genom Expression Microarray. Differentially expressed genes
at 4 week demyelination, acute and full remyelination were then compared to published transcriptomes of MS lesions. The CSF proteome was
established by liquid chromatography mass spectrometry (LC-MS/MS) in a discovery MS cohort (cohort 1, altogether 30 samples). Protein products
of overlapping orthologous CPZ/MS genes were then screened in this MS-CSF proteome. Next, levels of selected 129 peptides of 51 proteins of
orthologous CPZ/MS genes were measured in altogether 97 individual MS samples (cohort 1 and 2) by targeted proteomics (parallel reaction
monitoring, PRM), and stratified according to relapsing and progressive MS subtypes. The differentially regulated proteins were correlated with
concentration of molecular markers of inflammation and axonal degeneration (neurofilament light chain, NFL) [15] in the MS-CSF. The expression
kinetics of orthologous genes and proteins was examined by immunohistochemistry (IHC) in the CPZ model and related to demyelination, acute
remyelination and full remyelination.
https://doi.org/10.1371/journal.pone.0202530.g001
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antigen retrieval using antibodies against apolipoprotein C-II (MyBioSource, MBS2006755),
TIMP-1 (R&D systems, AF980-SP), tyrosine protein kinase receptor UFO (Santa Cruz Bio-
technology, sc-166269), Mac3 (Becton & Dickinson #553322), NG2 (Millipore AB 5320), and
CNP (Sternberger Monoclonals SMI 91).
Proteomics and parallel reaction monitoring (PRM)
Sample preparation and qualitative mass spectrometry (proteomics-discovery
step). 20 uL of 10 CSF samples for each of the groups: controls, RR, SP and PPMS were
pooled separately. Proteins were ethanol/acetone precipitated, redissolved in 7M, 2M thiourea,
20mM DTT. Protein amount was estimated using Qubit Protein Assay (Thermo Fisher Scien-
tific). Following alkylation with IAA proteins were digested with trypsin (50:1 ratio) overnight
at 37˚C. Peptides were RP purified using home-made columns of R2 and R3 (Applied Biosys-
temsTM). Purified peptides were redissolved in 0.1% formic acid. One μg of peptide sample in
5 μL was loaded on a precolumn (3 cm long, 100 μm ID, packed with 5 μm C18 RP material
(Dr. Maisch, Ammerbuch-Entringen, Germany) using nano-Easy LC (Thermo Fisher Scien-
tific). Peptides were separated on a 18 cm long, 75 μm ID analytical column packed with 3 μm
C18 material (Dr. Maisch, Ammerbuch-Entringen, Germany) using 100 min gradient of 90%
ACN/0.1% FA (solvent B): 0% to 10% in 5 min, 10% to 34% (linear gradient) in 77 min, 34%
to 100% in 10 min and 8 min at 100%. Peptides were fragmented and detected in Q-Exactive
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The MS settings: Full MS:
Resolution at 60000, AGC target 3e6, Maximum IT 50 ms. MS2: ten MSMS events at 15000
resolution, AGC target 3e6, Maximum IT 50 ms, isolation window 1.0 m/z, NCE: 28. Raw data
were processed and proteins identified using ProteomeDiscoverer software v1.4 (Thermo
Fisher Scientific).
Selection of peptides for PRM. PeptideAtlas repository (http://www.peptideatlas.org),
available in-house data and data generated during present work (see above) were used to select
number of peptides for each of the 98 proteins. The main criteria for the selection were the
high frequency of observation in CSF samples and a length of peptide (up to 20 AA). Subse-
quently, aided by Skyline software (https://skyline.ms; v. 3.5.0.9319; MacCoss Lab, Department
of Genome Sciences, UW) a list of precursor ions m/z (charge state 2 to 4+ per peptide, if rele-
vant) for these peptides were generated and used to re-search for their presence in CSF pools
(see above). Finally, the list was shortened to comprise up to 4 peptides per protein based on
the intensity of detected peptides, and if not detected, then on the frequency of detection in the
PeptideAtlas repository. Synthetic standard (SIS; crude preparation), heavy K and R labelled
peptides, were purchased from JPT Peptide Technologies (www.jpt.com). Their quality was
tested by mass spectrometry analysis.
Sample preparation for mass spectrometry/PRM. Proteins in 100 uL of individual CSF
samples were ethanol/acetone precipitated and redissolved in 50 uL 3M urea/thiourea (3.5:1),
20 mM DTT (S1 Table). Protein amount was estimated by amino acid composition analysis.
10 μg (and if not available, less was taken and appropriate correction was later done to the final
PRM results) was brought to final 140 uL, samples comprised in total 7M urea and thiourea
(ratio 3.5 to 1) and 20 mM DTT. Cysteines were alkylated with 45 mM IAA and proteins
digested with trypsin (50:1). After digestion, the same amount of SIS peptide mix was added to
each sample and peptides were RP purified (as above). Purified peptides were dissolved in
0.1% FA (Solvent A).
PRM analysis. 0.5 μg of peptide sample in 5 μL was loaded on a precolumn (3 cm long,
100 μm ID, packed with 5 μm C18 RP material (Dr. Maisch, Ammerbuch-Entringen, Ger-
many) using nano-Easy LC (Thermo Fisher Scientific). Peptides were separated on a 18 cm
Multi-omics in multiple sclerosis
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long, 75 μm ID analytical column packed with 3 μm C18 material (Dr. Maisch, Ammerbuch-
Entringen, Germany) using 62 min gradient of 90% ACN/0.1% FA (solvent B): 8% for 5 min,
8% to 30% (linear gradient) in 44 min, 30% to 100% in 5 min and 8 min at 100%. Peptides
were fragmented and detected in Q-Exactive mass spectrometer (Thermo Fisher Scientific,
Bremen, Germany). The MS settings: Full MS: Resolution at 120000, AGC target 3e6, Maxi-
mum IT 30 ms, scan range: 325–1200 m/z. PRM (10 reaction between Full MS scan): Resolu-
tion at 15000, AGC target 3e6, Maximum IT 15 ms, isolation window 1.1 m/z, NCE: 32. MS
data were processed using Skyline. The low intensity of most of the detected peptides, originat-
ing from the investigated proteins resulted in poor MS2 spectra, therefore for the consistency,
peptide relative quantification was performed using MS1 intensity of the precursor ion nor-
malized to intensity of the corresponding SIS standard.
Statistical analysis
Raw RNA expression data obtained by the microarray were normalized to the 75th percentile
signal intensity and entities showing present call in all samples of a condition were kept. Dif-
ferentially expressed genes were selected when passing the signal intensity filter (entities where
at least 100 percent of samples in any 1 out of 4 conditions have values within cut-off) and
showing at least 2-fold statistically significant change (ANOVA and Tukey HSD post-hoc test,
with Benjamini-Hochberg Multiple Testing Correction p-value<0.05) between any of the
groups. To search for known pathways containing a significant overlap with the relevant pro-
teins, over-representation analysis from the Consensus Pathway Database (CPDB, http://cpdb.
molgen.mpg.de/, Reslease 31), was performed. Ingenuity Pathway Analysis (IPA, http://www.
ingenuity.com) software was used to identify upstream transcriptional regulators that can
explain the observed transcription profile. Gene expression data was examined by the
Upstream Regulator module of IPA. The prediction of potential regulatory networks was
based on Ingenuity Knowledge Base, a very abundant collection of functional gene interactions
obtained by manual curation of biomedical literature and biological databases.
If not otherwise stated, statistical tests were performed using Prism 5 software (GraphPath,
USA, CA). MesoScale and peptide data were analyzed by ANOVA. All statistical tests were fol-
lowed by an appropriate post hoc test and quantitative data are presented as mean ± SEM, and
p<0.05 is considered significant. Pearson correlation was used to examine correlation between
CSF proteins and biomarkers. All p-values were corrected for multiple-testing, using Benja-
mini-Hochberg.
Results
Differentially expressed genes in the de- and remyelinated corpus callosum
By using stereomicroscope, the corpus callosum was cut out from brain sections 2 weeks and 4
weeks after feeding CPZ to mice (early and full demyelination), as well as 2 days and 2 weeks
after suspending CPZ (acute and full remyelination) (Fig 1). The Agilent microarray identified
1239 differentially expressed genes in the de- and remyelinated corpus callosum (Fig 2A). The
highest number of differentially expressed genes was observed during acute remyelination
(n = 762), followed by early demyelination (n = 412) and full demyelination (n = 317); the
number of differentially expressed genes was markedly reduced by the time of full remyelina-
tion (n = 119) (Fig 2A). The majority of differentially expressed genes during 2 and 4 weeks
demyelination overlapped (n = 228); only 28% of differentially expressed genes during late, the
4-week demyelination were different from genes of 2-week demyelination (Fig 2A). Acute
remyelination in the CPZ model was accompanied by a large number of newly activated
genes: 63% of the differentially expressed genes were different from activated genes during
Multi-omics in multiple sclerosis
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Fig 2. Gene expression during experimental de- and remyelination and orthologous genes in MS lesions. (A)
Overlaps of differentially expressed (at least 2-fold change and statistically significant difference at corrected p<0.05)
genes in four CPZ-treated experimental conditions compared to the untreated controls are visualized by Venn
diagram. Intensity of filling grey colour indicates the relative percent of all genes shown. The transcriptome of
demyelination was determined after 2 and 4 weeks of CPZ administration (2-week DEM, 4-week DEM); remyelination
transcriptomes were determined 2 days and 14 days after suspending CPZ (acute and full remyelination; 2-day REM,
2-week REM). (B) Orthologous genes in MS and CPZ lesions were determined by comparing differentially expressed
genes in white matter and cortical lesions of MS patients and MS susceptibility genes to transcriptome signatures of
CPZ-induced demyelination at 2 and 4 weeks (2wD, 4wD), acute remyelination 2 days after suspending CPZ (2dR),
and during full remyelination 2 weeks after suspending CPZ (2wR). The heatmaps represent the expression of
orthologous: overlapping MS genes during demyelination and remyelination phases of the CPZ model.
https://doi.org/10.1371/journal.pone.0202530.g002
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4-week demyelination. The majority of these genes were also different from late (2-week)
remyelination: only 14% were shared with late remyelination. In contrast to different gene
expression between demyelination and acute remyelination, only 7% of differentially ex-
pressed genes related to late remyelination were different from acute remyelination (Fig 2A).
Orthologous genes of murine and MS lesion transcriptomes
Next, we linked differentially expressed genes in MS lesions to genes differentially expressed in
experimental de- and remyelinated lesions (Fig 2B): we compared published datasets of active,
chronic active, chronic, early and late lesions in the white matter, and cortical grey matter tran-
scriptomes in the MS brain [17–20] to the 1239 differentially expressed genes in the CPZ
model. We identified 91 overlapping orthologous genes: 26 of these were differentially
expressed in cortical lesions, and 65 were differentially expressed in white matter lesions. Two
of the genes (Mbp and Cmtm5) were differentially expressed in both kinds of lesions (Fig 2B).
We also found 7 susceptibility genes identified by GWAS, which were differentially expressed
in the de- and remyelinated corpus callosum (Fig 2B). Out of the overlapping orthologous
WM and cortical MS lesion genes, 42 genes were related to experimental demyelination, and
41 genes were related to remyelination. Pathway analysis of the orthologous genes was per-
formed. Out of 18 significantly regulated, demyelination-related pathways in MS lesions, 15
were related to lipid metabolism; in contrast, only 2 of the 10 remyelination-related pathways
were related to lipid metabolism (Table 1). This differential representation of lipid metabolism
pathways was also confirmed by the IPA (data not shown). Pathway analyses of the 98 ortholo-
gous genes suggested the importance of molecules TYROBP, TREM2, TNFRSF1A, CYBA, and
PSMB9 besides molecules related to lipid metabolism (Table 1). When upstream regulators of
the orthologous genes were analyzed, three pathways emerged: up-regulated IL-15/IFN-γ/
STAT3 and TNF/IFN-γ/STAT3/IL-1β, and down-regulated SCAP/SREBF1/SREBF2 (Fig 3).
The differentially expressed genes of the downregulated SCAP/SREBF1/SREBF2 orthologous
pathway (Mvd, Elovl6, Acsl1, Dhcr7) were all downregulated during 2-weeks and 4-weeks
demyelination, and acute remyelination. The differentially expressed genes of the upregulated
IL-15/IFN-γ/STAT3 and TNF/IFN-γ/STAT3/IL-1β, orthologous pathways were all upregu-
lated during demyelination, acute and full remyelination, but with different kinetics: three
genes (Timp1, Psmbp9, Ifi35) peaked during acute remyelination, Cd74 peaked during full
remyelination, and Angptl4 reached a plateau from 2-weeks demyelination till full
remyelination.
Identification of 19 proteins of the 98 orthologous genes in the full CFS
proteome (cohort 1)
We then examined, if proteins reflecting the 98 orthologous genes could be detected in the
proteome of human CSF obtained from patients with RRMS, SPMS and primary progressive
MS (Fig 1). Twenty μl of CSF from 10 subjects in each of the 3 groups were pooled and exam-
ined by LC-MS/MS (discovery cohort). We detected 19 corresponding proteins out of the 98
orthologous differentially expressed genes in the full CSF proteome (Table 2).
Selection of 51 proteins for targeted proteomics and design of peptide
library
Next, we designed a targeted proteomics approach (PRM) to quantify and compare the level of
proteins of the 19 orthologous genes in additional CSF of relapsing and progressive MS
(cohort 2). However, we considered that potential proteins might be missed in the CSF
Multi-omics in multiple sclerosis
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proteome because of the low volume of the examined CSF and low number of subjects in the
LC-MS/MS analysis. Therefore, we selected 32 additional genes from the CPZ datasets for pro-
tein quantification in the CSF based on biological significance, cell surface expression, poten-
tial release upon cellular damage, and overlap with orthologous genes differentially expressed
in cortical or WM lesions from patients with MS (Table 2). Out of the total 51 selected genes
for targeted proteomics, 24 were expressed in WM lesions of MS brain, 9 genes were expressed
in cortical lesions, and 4 were GWAS genes (S2 Table). For each of the 51 genes, 2–4 peptide
sequences representing the corresponding proteins were designed based on in-house prote-
ome data of human blood, CSF, brain and cell cultures (S2 Table).
Measuring levels of the 129 peptides in 97 CSF samples (cohort 1 and 2)
By using the established peptide library representing the 51 proteins, we measured the levels of
the 129 peptides in 97 individual CSF samples by PRM: 57 patients with progressive MS (30
PPMS, 27 SPMS) and 40 patients with RRMS. We could detect 24 peptides of 10 proteins in all
97 CSF samples (S3 Table).
Table 1. Pathways of orthologous genes differentially expressed in both experimental de/remyelination and MS lesions.
Pathway p-value q-value source members
WM+ corticalMS lesion versus experimental demyelination
stearate biosynthesis 0.0004 0.006 HumanCyc ACSL1; ELOVL1
cholesterol biosynthesis 0.0006 0.006 Wikipathways MVD; DHCR7
PPAR signaling pathway 0.0006 0.006 KEGG LPL; ACSL1; ANGPTL4
synthesis of very long-chain fatty acyl-CoAs 0.0008 0.006 Reactome ACSL1; ELOVL1
omega-3 fatty acid metabolism 0.0009 0.006 EHMN ACSL1; ELOVL1
activation of gene expression by SREBP (SREBF) 0.001 0.006 Wikipathways MVD; DHCR7
metabolism of lipids and lipoproteins 0.001 0.006 Reactome SYNJ2; ACSL1; DHCR7; LPL; MVD; ELOVL1
fatty Acyl-CoA biosynthesis 0.001 0.006 Reactome ACSL1; ELOVL1
cholesterol biosynthesis 0.002 0.0065 Reactome MVD; DHCR7
activation of gene expression by SREBF (SREBP) 0.002 0.0065 Reactome MVD; DHCR7
superpathway of cholesterol biosynthesis 0.002 0.007 HumanCyc MVD; DHCR7
regulation of cholesterol biosynthesis by SREBP (SREBF) 0.002 0.007 Reactome MVD; DHCR7
amb2 Integrin signaling 0.0025 0.007 PID RAP1A; JAM3
omega-6 fatty acid metabolism 0.003 0.009 EHMN ACSL1; ELOVL1
fatty acid beta oxidation 0.005 0.01 Wikipathways ACSL1; LPL
triglyceride biosynthesis 0.006 0.01 Reactome ACSL1; ELOVL1
class I PI3K signaling events 0.009 0.02 PID CYTH1; RAP1A
integrated breast cancer pathway 0.009 0.02 Wikipathways XRCC3; RAP1A
WM+ corticalMS lesion versus experimental remyelination
glial cell differentiation 0.0002 0.006 Wikipathways MBP; MAG
osteoclast differentiation 0.0003 0.006 KEGG TYROBP; TNFRSF1A; CYBA; TREM2
other semaphorin interactions 0.001 0.02 Reactome TYROBP; TREM2
RANKL 0.002 0.02 NetPath TYROBP; TREM2
basigin interactions 0.002 0.02 Reactome SLC7A7; MAG
spinal cord injury 0.003 0.02 Wikipathways MBP; AIF1; MAG
hiv-1 nef: negative effector of fas and tnf 0.008 0.04 BioCarta GSN; TNFRSF1A
cardiac hypertrophic response 0.0085 0.04 Wikipathways FGFR2; TNFRSF1A
DAP12 signaling 0.009 0.04 Reactome TYROBP; FGFR2; TREM2
caspase cascade in apoptosis 0.009 0.04 PID GSN; TNFRSF1A
https://doi.org/10.1371/journal.pone.0202530.t001
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Differential regulation of 4 peptides representing 4 proteins in 97 CSF
samples
The levels of the detected 24 peptides normalized to synthetic standards (S3 Table) were
then compared among the 3 MS subgroups. Four peptides representing 4 proteins were
differentially regulated: tissue inhibitor of metalloproteinase-1 (TIMP-1, GFQALGDAADIR),
apolipoprotein C2 (APOC2, TAAQNLYEK), tyrosine-protein kinase receptor UFO (UFO,
APLQGTLLGYR), and beta2 microglobulin (B2M, VNHVTLSQPK) (Fig 4, S4 Table). All
these proteins were detected in the CSF in the discovery phase by LC-MS/MS (Table 2).
APOC2 peptide was upregulated in SPMS compared to RRMS. The other 3 peptides (TIMP-1,
Fig 3. Upstream regulators of up- and down-regulated orthologous genes in the cuprizone model and MS lesions. Upstream regulators of up- and down-regulated
orthologous genes were determined by Ingenuity Pathway Analysis. The experimentally observed gene expression tendencies are shown by the bottom line of nodes of the
graphs (red increased, green decreased expression), while the networks above these genes displays the predicted regulatory networks might be responsible for the detected
transcription effect. Orange color in the regulatory network indicates positive and blue color indicates negative regulatory effects. Marks on the graph edges shows the type
of functional interactions (E: expression, LO: localization, A: activation, TR: translocation, T: transcription, RB: regulation of binding, PD: protein-DNA binding, P:
phosphorylation) and the number of the supporting evidences in Ingenuity Knowledge Base.
https://doi.org/10.1371/journal.pone.0202530.g003
Multi-omics in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0202530 August 16, 2018 11 / 26
Table 2. Orthologous cuprizone and MS lesion genes detected in the CSF by proteomics and selected for targeted proteomics.
Protein Gene Description CPZ MS GWAS
Detected by proteomics in the CSF
APOC2 APOC2 Apolipoprotein C-II DEM up up1 no
LEG1 LGALS1 Galectin-1 DEM up up2 no
TIMP1 TIMP1 Metalloproteinase inhibitor 1 DEM up up1 no
ATS1 ADAMTS1 Disintegrin and metalloproteinase DEM down up2 no
HEP2 SERPIND1 Heparin cofactor 2 DEM down down3 no
MOG MOG Myelin-oligodendrocyte glycoprotein DEM down down3 no
CNTN2 CNTN2 Contactin-2 DEM down down3 no
DBND2 DBNDD2 Dysbindin domain-containing protein 2 DEM down up2 down3 no
UFO AXL Tyrosine-protein kinase receptor UFO eREM up up2 no
TREM2 TREM2 Triggering receptor expressed on myeloid cells 2 eREM up up1 no
MAG MAG Myelin-associated glycoprotein eREM down up2 no
KLK6 KLK6 Kallikrein-6 eREM down down3 no
DHPR QDPR Dihydropteridine reductase eREM down down3 no
FGFR2 FGFR2 Fibroblast growth factor receptor 2 eREM down down3 no
GELS GSN Gelsolin eREM down down3 no
B2MG B2M b2-microglobulin DEM, REM up up2 no
LYSC LYZ Lysozyme C DEM, REM up down2 no
BGH3 TGFBI Transforming growth factor,-beta-induced - up2 no
HPT HP Haptoglobin - up2 no
Additional genes selected for targeted proteomics
ANGL4 ANGPTL4 Angiopoietin-related protein 4 DEM up ac up no
CD83 CD83 CD83 antigen DEM up - no
GDF15 GDF15 Growth/differentiation factor 15 DEM up ac, chr up no
IGF1 IGF1 Insulin-like growth factor I DEM up - no
S10A4 S100A4 Protein S100-A4 DEM up - no
SLAF5 CD84 SLAM family member 5 DEM up - no
CERS2 CERS2 Ceramide synthase 2 DEM down - no
CKLF5 CMTM5 CKLF-like MARVEL transmembrane domain-containing protein 5 DEM down - no
DHCR7 DHCR7 7-dehydrocholesterol reductase, pathway cholesterol biosynthesis DEM down - no
EDIL3 EDIL3 EGF-like repeat and discoidin I-like domain-containing protein 3 DEM down - no
ELOV1 ELOVL1 Elongation of very long chain fatty acids protein 1 DEM down - no
ERBB3 ERBB3 Receptor tyrosine-protein kinase erbB-3 DEM down - no
IL12R1 IL12RB1 Interleukin-12 receptor subunit beta-1 DEM down chr up yes
IL33 IL33 Interleukin-33 DEM down - no
ITB4 ITGB4 Integrin beta-4 DEM down - no
LDLR LDLR Low-density lipoprotein receptor DEM down - no
LPAR1 LPAR1 Lysophosphatidic acid receptor 1 DEM down - no
SYNJ2 SYNJ2 Synaptojanin-2 DEM down - no
AIF1 AIF1 Allograft inflammatory factor 1 eREM up - no
CNTF CNTF Ciliary neurotrophic factor eREM up - no
HCST HCST Hematopoietic cell signal transducer eREM up - no
IRF8 IRF8 Interferon regulatory factor 8 eREM up - yes
MYOF MYOF Myoferlin eREM up - no
SNG1 SYNGR1 Synaptogyrin-1 eREM up - no
TNR1A TNFRSF1A Tumor necrosis factor receptor superfamily member 1A eREM up - yes
TYOBP TYROBP TYRO protein tyrosine kinase-binding protein eREM up - no
(Continued)
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UFO, B2M) were downregulated in PPMS compared to RRMS. In addition, UFO peptide was
also down-regulated in SPMS (Fig 4).
Correlation of TIMP-1, APOC2, UFO, and B2M levels with inflammatory
markers and neurofilament in the CSF
We next examined, if the level of the 4 peptides differentially expressed in MS subgroups correlate
with concentration of 36 neuroinflammatory markers and neurofilament light chain (NF-L) in
the CSF of 17 patients with RRMS. The level of UFO peptide APLQGTLLGYR and TIMP-1
peptide GFQALGDAADIR negatively correlated with the concentration of IL-6. Peptide
APLQGTLLGYR of UFO also negatively correlated with concentration of CCL2/MCP-1. Peptide
VNHVTLSQPK of B2M also negatively correlated with the concentration of CCL17/TARC. In
contrast, peptide TAAQNLYEK of APOC2 showed positive correlation with the concentration of
IL-16, IL-2 and CCL26/eotaxin-3 (Fig 5). NF-L showed no correlation with the 4 peptides.
We also examined the correlation among the 4 peptides in the CSF of the same 17 patients
with RRMS. We found that B2M correlated with levels of both UFO (p<0.0001, r = 0.91) and
TIMP-1 (p<0.01, r = 0.71), and we also found correlation between TIMP-1 and UFO (p<0.01,
r = 0.64).
Genes and proteins of TIMP-1, APOC2, UFO, and B2M are over-expressed
during acute remyelination
To investigate if the expression of the 4 orthologues (TIMP-1, APOC2, UFO, and B2M) is
related to de- or remyelination, and explore the dynamics of expression, we examined changes
in the gene and protein expression of the 4 orthologues during experimental de- and remyeli-
nation in the CPZ model. All four genes peaked during acute remyelination, and the gene
encoding TIMP1 was also upregulated during demyelination (Fig 6).
To examine the protein expression and validate microarray data, we examined the expres-
sion of TIMP-1, APOC2, and UFO by immunohistochemistry in different tissues and in the
brain of mice during CPZ-induced de- and remyelination. In the normal mouse brain, we
found some expression of UFO within large neurons and minor reactivity on glia (most likely
astrocytes) in the pons and CC (Fig 7). In mice treated with CPZ, we found mildly increased
immunoreactivity in neurons in the pons (data not shown). Within the demyelinating CC, we
found clear reactivity on macrophages/microglia; similar reactivity was seen during acute
Table 2. (Continued)
Protein Gene Description CPZ MS GWAS
TEFF2 TMEFF2 Tomoregulin-2 eREM down - no
STMN4 STMN1 Stathmin eREM down - no
MBP MBP Myelin basic protein eREM down - no
G3ST1 GAL3ST1 Galactosylceramide sulfotransferase eREM down - no
PSYR GPR65 Psychosine receptor DEM, REM up ac, chr up yes
UBD UBD Ubiquitin D - ac up no
DEM: demyelination; REM: remyelination; eREM: early remyelination; chr: chronic; ac: acute;
1[19];
2[18];
3[17]
https://doi.org/10.1371/journal.pone.0202530.t002
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Fig 4. Differential regulation of 4 peptides in the CSF of patients with relapsing and progressive MS. Level of peptides relative to the
respective stable isotope standard is indicated by scatter plots, and was quantified by targeted proteomics, parallel reaction monitoring in the
CSF of patients with relapsing-remitting MS (RRMS, n = 40), secondary progressive MS (SPMS, n = 27), and primary progressive MS (PPMS,
n = 30). (ANOVA, corrected for multiple-testing, using Benjamini-Hochberg). See also S1 and S3 Tables.
https://doi.org/10.1371/journal.pone.0202530.g004
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remyelination (Fig 7). These data suggest that major up-regulation of UFO within the CPZ
lesions is due to its expression in macrophages/microglia.
We found expression of TIMP-1 on the nuclear membrane of large neurons and minor reac-
tivity in glia in the control animals (data not shown). In the CPZ lesions, we found reactivity in
some cells, which by morphology are most likely oligodendrocytes or OPCs; this reactivity was
increased during demyelination and acute remyelination in the CC, but not in the pons (Fig 7).
In the control brain, APOC2 immunoreactivity was seen in neurons and prominently in a
subset of endothelial cells of vessels (data not shown). In the CPZ lesions, expression in endo-
thelial cells was low or absent, but there was a variable degree of granular reactivity in macro-
phages, which was more pronounced during acute remyelination compared to demyelination
(Fig 7).
Fig 5. Correlation of peptide levels with pro-inflammatory markers in the CSF of patients with relapsing-remitting MS. The concentration of the indicated
biomarkers was examined by MesoScale Discovery technique, and the levels of peptides were quantified by parallel reaction monitoring in the CSF of 17 patients with
RRMS.
https://doi.org/10.1371/journal.pone.0202530.g005
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Fig 6. Experimental de- and remyelination kinetics of 4 genes with differentially regulated orthologues in the MS CSF. Relative
expression of orthologous mouse genes of the 4 proteins was examined in the corpus callosum of control mice and during different
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Discussion
Here, we applied a multi-omics approach to examine molecular pathways related to cellular
responses that are associated with de- and remyelination in MS lesions, and used these find-
ings to discover molecules that are differentially regulated in the CSF proteome among MS
subtypes. We first examined the transcriptome signature of experimental de- and remyelina-
tion, and compared these to MS lesion transcriptomes in order to identify de- and remyelina-
tion related pathways and molecules in MS. We then examined the CSF proteome in a
discovery MS cohort by LC-MS/MS, and protein products of the overlapping orthologous
genes were screened in the CSF proteome. Based on these data, we designed 129 peptides that
represented the orthologous genes, measured them in 97 CSF samples of additional MS
patients (cohort 1 and 2), and compared their levels between relapsing and progressive MS
subtypes. Peptides that were differentially regulated between RRMS and progressive MS were
correlated with molecular markers representing inflammation, BBB dysfunction, and axonal
damage. Finally, the expression kinetics of orthologous genes of the differentially regulated
proteins were examined in the CPZ model, and related to experimental demyelination, acute
and full remyelination.
phases of CPZ-induced demyelination (2 weeks, n = 3; and 4 weeks, n = 4), and acute and full remyelination (2 days after suspending
CPZ, n = 3; and 14 days after suspending CPZ, n = 3) by 4x44K Agilent Whole Mouse Genom Expression Microarray. Mean of relative
expression is shown at these time points.
https://doi.org/10.1371/journal.pone.0202530.g006
Fig 7. Expression of differentially regulated orthologous proteins in the CSF of patients with MS during CPZ-induced de- and remyelination. Protein
expression of the indicated proteins have been examined by immunohistochemistry in the corpus callosum of controls, 4 weeks after CPZ administration
(demyelination), and 2 days after suspending CPZ (acute remyelination). Blank indicates no antibody. Magnification bars represent 100 micrometer.
https://doi.org/10.1371/journal.pone.0202530.g007
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In the animal model, the majority of differentially expressed genes during 2 and 4 weeks
demyelination overlapped, and almost all differentially regulated pathways were related to
lipid metabolism. We found the greatest rearrangement of gene expression during acute
remyelination, indicating a rapid activation of genes. Many of the differentially regulated path-
ways/genes during acute remyelination, i.e. 2 days after suspending CPZ were associated with
immune responses. Since adaptive immune responses are absent or minor in the CPZ model,
this may reflect rapid microglia responses during acute remyelination. By the time of late
remyelination (2 weeks), the majority of these genes (85%) were not differentially expressed,
and only 7% were newly expressed.
We next compared the transcriptome signatures of experimental de- and remyelination to
a wide variety of MS lesion transcriptomes: active, chronic active, chronic lesions, early and
late lesions, cortical and white matter lesions [17–20]. The orthologous CPZ/MS genes repre-
sented pathways of lipid metabolism, cell death and survival, and inflammatory responses.
Besides lipid metabolism, pathway analysis of the orthologous CPZ/MS genes suggested the
importance of TNFRSF1A encoding TNF receptor 1, CYBA (cytochrome b-245 alpha subunit)
required for enzymes producing reactive oxygen species [21], PSMB, a proteasome subunit
that is important in antigen presentation and regulation of apoptosis [22], and TREM2, TYR-
OBP. In the CNS, TREM2 is expressed exclusively by microglia [23], and is crucial in basic
microglia functions: ligation of TREM2 induces downstream signaling through its signaling
partner TYROBP/DAP12 [24], and results in cellular activities in microglia including promo-
tion of phagocytosis, survival, proliferation and inflammatory responses [25–27]. TREM2
through mTOR signaling is also important in maintaining the metabolic state of microglia and
may serve as a sensor of stress [28]. Loss-of function mutations in TREM2/TYROBP/DAP12
cause myelin loss Nasu-Hakula disease indicating their role in maintaining CNS myelin integ-
rity [25]. Thus, in both MS and in the cuprizone model, the upregulated TREM2/TYROBP
pathway may indicate microglia activation reacting to myelin damage and/or apoptosis of oli-
godendrocytes. Indeed, in Trem2-deficient mice, activation of microglia and myelin clearance
is deficient in the cuprizone model, and axonal injury is increased [29]. This may be explained
by inability to sense myelin damage. In EAE, TREM2 is upregulated in microglia, and blocking
TREM2 exacerbates disease [30]. These animal models may suggest a beneficial role of
TREM2 in demyelinating diseases, and considering our data indicating TREM2/TYROBP as
an orthologue CPZ/MS pathway, upregulation of TREM2/TYROBP may be also beneficial in
MS. However, in recent neurodegenerative models with early pathology, targeting the
TREM2/TYROBP-APOE pathway restored the homeostatic signature of microglia, and
reduced neurodegeneration and neuroinflammation [27,31,32]. We also found that Apoc2
was upregulated in the de- and remyelinating corpus callosum in the CPZ model, and APOC2
was detected in the CSF of patients with MS. One of the mechanisms of sensing stress by
TREM2 on microglia may be binding to phosphatidylserins and other phospholipids on the
surface of stressed or apoptotic cells [25,33]. TREM2 is also able to bind apolipoproteins, i.e.
APOE, APOA1, APOA2, APOD and APOE [25]. If APOC2 can be another binding ligand for
TREM2 is unclear.
Upstream regulators of the orthologous CPZ/MS genes focused attention on several addi-
tional molecules: upregulated pathways of IL-15, IFN-γ, STAT3, TNF, and IL-1β; and down-
regulated pathways of SCAP. IL-15 enhances the cytotoxic effect of lymphocytes; it is elevated
in the serum and CSF of patients with MS and expressed on astrocytes in MS lesions [34,35].
SCAP (sterol regulatory element binding protein cleavage activation protein) control choles-
terol synthesis [36]. In the upstream regulator orthologous pathways, all genes in the SCAP
pathway were downregulated during demyelination (Mvd, Elovl6, Acsl1, Dhcr7); in contrast, in
the upregulated inflammatory pathways three out of the five genes peaked during acute
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remyelination (Timp1, Psmbp9, Ifi35), one peaked during full remyelination (Cd47), and one
gene reached a plateau during early demyelination that persisted during acute remyelination
(Angptl4). These data indicate again that differentially expressed orthologous MS genes related
to remyelination are associated with inflammatory responses most probably by microglia.
Next, we used the CPZ and the orthologous MS gene data sets for identifying molecules
that are differentially expressed in the CSF of relapsing and progressive MS by using a multi-
omics method. We applied a two-step approach of CSF proteomics: (i) we first identified pro-
tein products of orthologous genes in the CSF proteome, and (ii) used a targeted quantitative
approach to validate and compare the levels of specific proteins among MS subtypes. Using
this approach, we focused on those proteins that were differentially expressed in MS lesions as
genes, and were related to de- and remyelination. We identified 4 proteins differentially regu-
lated between relapsing and progressive MS: UFO, TIMP-1, APOC2, and B2M.
One of the overlapping CPZ/MS gene orthologues, UFO protein, a receptor tyrosine kinase
belonging to the family of TAM receptors, was upregulated in the CSF proteome of patients
with relapsing compared to progressive MS. In the CPZ model, UFO protein was upregulated
on macrophages/microglia in the demyelinating and acute remyelinating corpus callosum,
while expressed at low levels in the normal mouse brain. This pattern of upregulation and cel-
lular source is compatible with the function of UFO, as its plays a role in clearing myelin debris
and apoptotic cells [37]. In the absence of Axl and/or its ligand growth-arrest-specific protein
6 (Gas6), remyelination is delayed, axonal damage is more severe, and inflammation is more
pronounced [38–41]. We also found that higher level of UFO was associated with lower CCL2/
MCP-1 concentrations in the CSF. CCL2/MCP-1 regulates the migration of monocytes/mac-
rophages, and both are upregulated in MS lesions [42,43]. Higher level of UFO in the CSF of
RRMS was also associated with lower concentration of IL-6 that disrupts the integrity of the
BBB, and promotes autoimmune CNS response [44]. UFO-deficient (Axl-KO) mice had also
more severe clinical course of EAE, which indicates a protective role of UFO in the inflamma-
tory model of MS [37]. Altogether, these data support the notion that UFO may contribute to
tissue repair and less inflammation both in MS and experimental demyelination partially by
promoting phagocytosis by microglia and reducing inflammation.
Another overlapping CPZ/MS gene orthologue, TIMP-1 was also upregulated in the CSF
proteome of relapsing versus primary progressive MS. In the CPZ lesions, we found reactivity
in cells, which by morphology are most likely oligodendrocytes or OPCs; this reactivity was
increased during demyelination and further increased during acute remyelination. Besides reg-
ulating MMP-9 [45,46], TIMP-1 also exhibits a trophic, growth factor function: it promotes
astrocyte recovery [47], OPC differentiation [48], and activates PI3K and Akt signaling [49].
TIMP-1 is also expressed in immature astrocytes [48]. We may speculate that our observation
of TIMP-1 expression on oligodendrocytes/OPCs may be related to their differentiation and
survival during demyelination and especially during remyelination. In line with our results,
Timp-1 mRNA has been described to be upregulated during demyelination and in the acute
remyelination phase [50]. TIMP-1 is upregulated in cortical MS lesions [18], and its restricted
expression promotes EAE pathology [51]. Low levels of TIMP-1 and high MMP-9 concentra-
tion in both CSF and serum may be a marker of MRI disease activity, and their ratio may esti-
mate the integrity of the BBB [52,53]. We also found that levels of TIMP-1 in the CSF of RRMS
negatively correlated with the concentration of IL-6, which may support the beneficial role of
elevated TIMP-1 in controlling inflammation and possibly BBB damage, similar to UFO.
A third orthologue, B2M was also upregulated in relapsing versus primary progressive MS.
B2M constitutes the light chain of MHC I proteins that are expressed by all nucleated cells. It
is released during metabolism and degradation, and thereby reflects cell membrane removal
and cellular turnover. The presence of B2M in the CSF may be a CNS inflammatory or tumor
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marker [54]. In our study, the level of B2M showed a week negative correlation with CSF con-
centration of CCL17/TARC that induces chemotaxis of T cells through CCR4. In a recent
study, we found higher concentration of CCL17/TARC in SLE-associated NMOSD, and
CCL17/TARC correlated with AQP4-antibody, anti-nucleosome, anti-dsDNA, and CXCL10/
IP-10 levels [55]. Increased B2M gene expression in CPZ lesions may also indicate microglia
responses related to demyelination and acute remyelination; such responses may be benefi-
ciary by removing myelin debris and limiting inflammation.
In summary, the levels of UFO, TIMP-1 and B2M were higher in RRMS compared to pro-
gressive MS types; they correlated negatively with pro-inflammatory markers in the CSF; and
also showed a strong positive correlation with each other.
In contrast to these three orthologues, the fourth orthologue, APOC2 was upregulated in the
CSF proteome of progressive compared to relapsing MS, and this molecule is directly related to
lipid metabolism in the brain [56]. APOC2 is a cofactor for the activation of lipoprotein lipase
that mediates hydrolysis of triglycerides, and plays an important role in the transport of lipids in
the CNS [57,58]. Apolipoprotein C2 deficiency is related to a lipid encephalopathy and spinocere-
bellar ataxia type 12 [59,60]. In contrast to the other three orthologues, APOC2 level in the CSF
showed a strong positive correlation with the concentration of proinflammatory IL-2, IL-16, and
CCL26/eotaxin-3. In MS and EAE, IL-16 is an important chemotactic factor for CD4+ T cells, and
has been observed within the perivascular infiltrates [61]. APOC2 has been identified as a poten-
tial risk gene for MS, although this finding has been questioned by others [62–64].
UFO, TIMP-1, B2M and APOC2 all had similar expression profiles in the CPZ model: the
peak gene expression was observed during acute remyelination, and up-regulated proteins
were found during demyelination and acute remyelination. Nevertheless, the cellular source of
these molecules may be different: UFO and APOC2 showed reactivity with macrophages/
microglia, while TIMP-1 was upregulated most likely on oligodendrocytes or OPCs. These
data may indicate that although these proteins have been related to de- and remyelination,
they reflect different cellular responses including microglia activation. Indeed, microglia-
related 24 genes (surface markers and phagocytosis-related genes) peaked during acute remye-
lination in our study; nevertheless, the oligodendrocyte precursor cell gene of NG2 was also
upregulated during acute remyelination (data not shown).
Finally, we used the CSF-PR 2.0 database to examine if these 4 proteins have been previously
detected and quantitatively changed in the CSF proteome of patients with MS [65]. This data-
base search indicated that all of these 4 proteins have been previously detected in the CSF prote-
ome of patients with RRMS. The level of TIMP-1 was increased in the CSF proteome of patients
with RRMS compared to controls with other neurological diseases and healthy subjects [66–68],
but there was no difference comparing patients with early MS to clinically definite MS [69]. The
level of UFO was not different in the CSF proteome of early MS or RRMS compared to other
neurological disease controls [66,67,69]. The level of B2M was increased in the CSF of proteome
of patients with RRMS compared to other neurological disease controls [66,67], while other
studies did not find such differences [66,67]. The level of APOC2 was not different in the CSF
proteome of patients with RRMS and other neurological disease controls [66,67].
Conclusion
Our study used a comprehensive, translational multi-omics approach. The differential gene
expression during experimental de- and remyelination was compared to MS lesion transcrip-
tomes, and overlapping orthologues were screened at protein levels in the CSF proteome of
MS patients. Finally, 129 peptides of selected 52 protein orthologues were quantitatively mea-
sured in 97 individual CSF, respectively. Their levels were compared between relapsing and
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progressive MS, were correlated with inflammatory markers in the CSF, and were related to
gene and protein expression kinetics in experimental de- and remyelination. We could con-
clude that (i) experimental demyelination was mainly associated with altered lipid metabolism,
while acute remyelination was associated with a profound change in gene activation. Many of
the upregulated genes during acute remyelination were related to immune responses, and
overlapped with orthologues in MS lesions. In fact, (ii) three out of four protein orthologues
that were differentially regulated in the CSF proteome of relapsing and progressive MS were
not directly related to myelin metabolism, but to pathways important in cell survival and
immune responses. (iii) Since adaptive immune responses are absent or minor in the CPZ
model, our data may indicate the role of microglia during acute remyelination, and different
cellular responses promoting oligodendrocyte survival; the TREM2/TYROBP orthologous
pathway may be important in such processes. (iv) These events were reflected in the CSF pro-
teome of patients with MS. (v) Interestingly, the three CPZ/MS orthologues that were upregu-
lated in the CSF proteome of relapsing compared to progressive MS, were all negatively
correlated with inflammatory molecules, while positively correlated with each other. Although
their cellular source maybe different, previous data indicated their protective role in experi-
mental models: UFO (Axl) promotes remyelination and oligodendrocyte survival and limits
inflammation [29–33,41]; TIMP-1 limits inflammation, blood-brain barrier damage, and pro-
motes OPC differentiation [46–50]; B2M may indicate microglia activation related to removal
of myelin debris and limiting inflammation in the cuprizone lesions; soluble B2M in the MS
CSF may indicate increased cellular metabolism and degradation in the CNS. Thus, (vi)
increased levels of UFO, TIMP-1 and B2M in the CSF of patients with relapsing MS may indi-
cate different cellular processes in the brain related to de- and remyelination that aim reducing
inflammation and promoting survival of oligodendrocytes and their precursor cells. (vii)
These processes are either less pronounced in the brain, or less reflected in the CSF in progres-
sive MS. (viii) The only orthologue that were upregulated in the CSF proteome of progressive
versus relapsing MS was APOC2 that is related to cholesterol metabolism in the brain. In con-
trast to the other three orthologues, APOC2 level showed a strong correlation with the concen-
tration of proinflammatory molecules IL-2, IL-16, and CCL26/eotaxin-3. This may indicate
that myelin and lipid-related pathological events in the CNS may be more pronounced (or
more reflected in the CSF) in progressive MS, nevertheless, they may be associated with
inflammatory responses even in this phase.
This study is not without limitations. The CSF full proteome was examined in 30 patients,
and only a low volume of samples were applied from each patient. However, we did not restrict
the design of the peptide library only to these findings, and the targeted proteomics was done
with a large number of individual CSF samples using higher volumes of CSF. Although we val-
idated the protein expression of UFO, APOC2 and TIMP-1 by immunohistochemistry, the
cell-specific expression was not addressed by specific antibodies. Nevertheless, this was not a
major aim of the study. The role of these identified four molecules as potential CSF biomarkers
should be validated in independent larger studies. Their biomarker potential and role in MS
pathogenesis are reflected by previous studies indicating their presence in the CSF proteome
of patients with RRMS, and upregulation of TIMP-1 and B2M in the CSF proteome of RRMS
compared to controls [65–69].
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